The prolonged survival of children, adolescents and young women successfully treated for cancer increases the number of women facing premature menopause (PM). 1-3 The complexity of their clinical picture, their increased vulnerability to accelerated ageing due to the combined effect of PM and the side effects of chemotherapy and/or radiotherapy and their expectations for a better quality of life (QoL) -both general and sexual -challenge the ability of physicians to provide appropriate, tailored medical and psychosexual treatment. 4, 5 
Given the trophic role of sexual hormones on body tissues, PM is associated with an increased risk of accelerated ageing; the younger the woman, the higher the risk, unless appropriate hormonal treatment (HT), when feasible, is initiated and adequately maintained at appropriate doses. 4, 5, 10 Morbidity and mortality from cardiovascular disease, stroke, accelerated brain ageing and osteoporosis present a greater risk in PM women compared with controls. Sexual dysfunctions are reported with higher frequency and more significant personal distress after surgical menopause. 10 Overall sense of wellbeing and achievement of life goalsspecifically having a partner, getting married, having a satisfying sexual life and having children -may be variably affected. 4, 5, 11 Fertility is a major issue in childless women facing PM. [1] [2] [3] This article will focus on the main characteristics of PM and its impact on accelerated general health and sexual ageing, with a specific focus on sexual identity, sexual function and sexual relationships. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 
Prevalence of Premature Menopause and Associated

Female Sexual Disorders
Spontaneous POF affects on average 1% of women under 40 years of age. 7, 9 Ethnicity is a contributor: the highest figure of POF is reported among African-American and Hispanic women (both 1.4%), and the lowest in Japanese women (0.1%). 16 Iatrogenic menopause for benign and malignant conditions affects 3.4-4.5% of women under 40. [1] [2] [3] [4] [5] 17 Systematic studies on the prevalence of female sexual disorders (FSDs) in women affected by PM are limited. The prevalence of low desire for younger surgically menopausal women is significantly higher (32%) than that found for pre-menopausal women of the same age (19%). The probability of hypoactive sexual desire disorder (HSDD) increases with age, while the distress associated with the loss of desire is inversely correlated with age. 18 
Aetiology and Diagnosis of Premature Menopause and
Health Vulnerabilities
Heterogeneity is the hallmark of the aetiology of PM, which can be genetic, autoimmune, associated with chronic diseases or iatrogenic in the context of benign or malignant disease 1-9 (see Table 1 ). PM impact on health and sexuality varies accordingly. It may be limited in women affected by POF who have a family and are on optimal HT. It may be dramatic when the consequences of PM are superimposed to a serious medical condition that currently contraindicates HT, such as breast cancer, and/or in a childless younger woman. 5, 19, 20 Multiple pathologies -and associated treatments -further increase the risk of accelerated ageing, as exemplified when PM is associated with cancer or autoimmune diseases.
Impending PM is hypothesised when menopausal symptoms leading to POF appear in women younger than 40 years of age. Predictors of PM include both poor response to ovarian stimulation and raised basal FSH. 
Gynaecological Endocrinology
Definite diagnosis is based on FSH levels above 40IU/l in two consecutive samples at one-month distance. 7, 9 Echography may show small ovaries for the age, with no or few residual oocytes. PM is implicit when bilateral oophorectomy is performed in women younger than 40 years of age.
Factors Modulating Ageing and Sexual Issues after Premature Menopause
The aetiology of PM is the single most powerful biological factor affecting quality of ageing and psychosexual outcome. Age at PM is critical -the earlier the PM, the more complex the impact on general health and sexuality. 4, 5 Sexual identity is more vulnerable when PM disrupts the process of psychosexual maturity, after peripubertal spontaneous POF or after iatrogenic POF, for childhood or adolescent cancers. 4, 5 Stage in life cycle may contribute to FSD, with fertility being a major issue in childless women and couples. [1] [2] [3] 5, 11 Body image concerns, skin changes, changes in body shape and tendency to weight gain and central adiposity may impair the sense of personal attractiveness, contributing to loss of self-confidence and self-esteem and a general sense of 'feeling and looking older'. 4, 5, [19] [20] [21] There is a higher risk of dismetabolic diseases -such as diabetes -in overweight PM women.
Corticosteroids, when needed to treat an autoimmune pathology -such as lupus erithematosus systemicus (LES) or rheumatoid arthritis (RA) -further increase this risk. Body image issues may become prominent in women who underwent breast or gynaecological oncological surgery and associated treatments causing PM. 5, [19] [20] [21] The woman's health, coping attitude and quality of sexuality before PM may all affect sexual outcome after PM. Women at higher risk of negative sexual outcome after PM are younger, single or in conflicting relationships, childless or with lower education and socioeconomic status. 5, [19] [20] [21] [22] The partner's reaction to the associated infertility and the quality of the relationship before and after PM further modulate the individual's and the couple's coping attitudes. Contextual factors -both relational and sociocultural, such as ethnicity -also contribute. 11
Pathophysiology of Sexual Dysfunction after Premature Menopause
Oestrogens and androgens modulate the neurobiology of brain ageing.
Their trophic role in neuronal membrane repair, in promoting neuronal sprouting and interneuronal connectivity and in controlling neurotransmitter levels, is gaining increasing evidence. They also modulate sexual desire and mental arousal, and the neurovascular cascade of events leading to genital arousal, lubrication and orgasm.
Oestrogens are modulators of sexual response and 'permitting' factors for vasoactive intestinal polypeptide (VIP), which 'translates' desire and central arousal into vaginal congestion and lubrication. Testosterone has an initiating role on desire and central arousal, acting on the dopaminergic appetitive-seeking pathway, and a modulator role on the peripheral response, as permitting factor for nitric oxide (NO), the main mediator of clitoral and cavernosal bodies congestion. 4, 5, 23 The loss of oestrogens and androgens contributes to impaired brain ageing, as exemplified by increased and anticipated neurovegetative, affective and cognitive disorders in PM women. It reduces sexual desire and central and peripheral arousal, causing vaginal dryness, and causes/worsens orgasmic difficulties and dyspareunia, leading to loss of self-confidence and self-esteem and an increase in anxiety and concern. The loss of sexual hormones may also contribute to the neurobiological aetiology of depressed mood that is so often co-morbid with acquired loss of desire, and potentiates the depressive feelings consequent to the many losses PM implies. 24 Co-morbidity of FSD is frequent. The issue of FSD cannot be separated from the impact on sexuality of concomitant medical co-morbidities associated with or consequent to different etiologies of PM. 5 
Diagnosis of Female Sexual Disorders after Premature Menopause
Treatment of Premature Menopause and Associated
Fertility Issues
Tailored HT is the treatment of choice in POF (when non-contraindicated, i.e. in survivors of breast cancer or genital adenocarcinoma, or after thromboembolic disease, acute hepatitis, etc.). Systemic oestrogen treatment (OT) is the choice in women who underwent hysterectomy besides oophorectomy. Topical vaginal OT may address vaginal atrophy and bladder symptoms when systemic OT is not suitable or desired.
Recommendations from the European Menopause and Andropause
Society (EMAS) 26 and the International Society of Menopause (ISM) 27 include treating PM with HT up until the age of natural menopause (51 years of age), unless a specific contraindication is diagnosed. 
Management of General Health and Sexual Issues Associated with Premature Menopause
The most important sexual issues are related to: 1) age, physical and psychological impact of PM; 2) effects of oestrogen and androgen loss on general and sexual health; 3) severity of menopausal symptoms; and 4) loss of fertility and its meaning to both partners. 5 An interdisciplinary approach offers the best opportunity to tailor treatment according to the needs of the woman and/or the couple. HT is the aetiological treatment, when feasible, that may minimise the impact of PM on general health and menopausal symptoms and signs. The focus here will be on treatment of FSD associated with PM.
Medical Management of Female Sexual Disorders
Desire and Central Arousal Disorders
Desire and central arousal overlap. Randomised controlled trials (RCTs) indicate the positive effect of testosterone in oestrogen-repleted women after surgical menopause, when aetiology appears to be hormonedependent. In RCTs, treatment with 300µg/day testosterone patches on oestrogen-repleted women significantly increased sexual desire and frequency of satisfying sexual activity, reduced sexual distress and was well tolerated. [12] [13] [14] [15] Two systematic reviews of RCTs indicate a positive effect of testosterone on all dimensions of sexual function, as well as some psychological benefits. 24, 30 Secondary outcomes indicate a significant improvement of arousal, orgasm, self-image and self-esteem, and a significant reduction in anxiety and concerns. The testosterone patch treatment was approved by the European Agency for the Evaluation of Medicinal Products (EMEA) in July 2006. However, controversy still exists with respect to the indication of androgen therapy in women. 31 Tibolone and HT with estradiol and noretisterone are other options to improve sexual desire. Bupropion is a non-hormonal drug that may also improve sexual desire.
Genital Arousal Disorders
Vaginal dryness -the most common complaint of genital arousal disorders -can be treated with vaginal oestrogens. 32 
